
Dec 16 (Reuters) - U.S. Health Secretary Robert F. Kennedy Jr. on Tuesday added two rare genetic disorders, Duchenne Muscular Dystrophy and Metachromatic Leukodystrophy, to the federal newborn screening list to enable early treatment, the Department of Health and Human Services said.
The decision updates the Recommended Uniform Screening Panel (RUSP), which guides state-level newborn screening programs, following a scientific review and public comment process.
Early detection of Duchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD) will allow children to receive FDA-approved therapies at the most effective time, helping slow disease progression and preserve quality of life, the HHS said.
DMD, a rare genetic disorder, causes muscle degeneration, while MLD affects the brain and nervous system, which leads to loss of motor and cognitive function and early death.
Most children with DMD or MLD are diagnosed at age four or five, when significant muscle loss or neurological decline has already occurred, the HHS said.
The agency said that screening at birth could reduce years-long diagnostic delays, repeated specialist visits, and the financial and emotional strain often associated with rare diseases.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Shinjini Ganguli)
It Looks Like a Tiny, Fluffy Dragon, But It's Really a Bird. Meet the Great Eared Nightjar
Deadly Switzerland ski resort fire was likely started by sparklers attached to champagne bottles, officials say
SpaceX rocket launches 140 satellites into orbit on Transporter-15, aces landing at sea (video)
Reality TV star Spencer Pratt, who lost his home in Palisades Fire, is running for mayor of Los Angeles
Trump announces 'Patriot Games' with 2 competitors from every state and territory: What we know
How to watch ‘The Traitors’ U.K. Season 4 premiere today from the U.S.
Tributes pour in for MIT professor Nuno Loureiro amid unresolved shooting case
'Inflaming tensions': Bedouin mayor slams Ben-Gvir's unauthorized visit after meeting cancellation
Impact of NIH funding reductions felt in cancer and infectious disease trials












